Functional Categories.

<p>Functional Categories.</p

Functional Ambulation Categories.

<p>Functional Ambulation Categories.</p

Descriptive Data Analysis of all 26 individuals.

<p>Descriptive Data Analysis of all 26 individuals.</p

Correlation Analysis at the 2 time points (N = 26).

<p>Correlation Analysis at the 2 time points (N = 26).</p

Summary of clinical parameters at each visit.

<p>Summary of clinical parameters at each visit.</p

Correlations between cytokines, pain and gait.

<p>Pearson correlation coefficient of the sample (r) was used to assess the correlation between reductions in TNF-α and IL-6 concentration (pg/ml) with improvements in the 10m TW (seconds) and pain (VAS) from D0 to D2. <b>A)</b> Correlation between TNF-α concentration and pain. <b>B</b>) Correlation between TNF-α concentration and 10m TW. <b>C</b>) Correlation between IL-6 concentration and pain. <b>D</b>) Correlation between IL-6 concentration and 10m TW.</p

Effect of methyl prednisolone on gait.

<p>A, Change in 10m timed walk as the median of the percentage difference (%) in comparison to D0. B, Correlation between the 10m TW (seconds) at D0 and an improvement in the 10m TW from D0 to D2 (seconds) using Pearson’s correlation coefficient of the sample (r). Outliers were excluded. C, Correlation between duration of disease and improvement in 10m TW. Scatter plot with line of best fit showing duration of disease (months) against the improvement in the 10m TW (seconds) at D2 using Pearson’s correlation coefficient of the sample (r). Outliers were excluded.</p

Summary of cytokine concentration in response to pulsed IV methylprednisolone.

<p>Summary of cytokine concentration in response to pulsed IV methylprednisolone.</p

Baseline demographics of the patients treated with methylprednisolone.

<p>Baseline demographics of the patients treated with methylprednisolone.</p

Flowchart of enrolment and follow up of patients with definite and early and/or progressing HAM/TSP.

<p>50 patients with HAM/TSP were identified and 9 were identified as patients with early and/or deteriorating HAM/TSP, 7 of whom consented to treatment with ciclosporin A. Two patients chose to re-start ciclosporin A after 48 weeks during trial period.</p